As of Apr 18
| +0.1209 / +17.02%|
The 2 analysts offering 12-month price forecasts for Conatus Pharmaceuticals Inc have a median target of 1.60, with a high estimate of 1.70 and a low estimate of 1.50. The median estimate represents a +92.52% increase from the last price of 0.83.
The current consensus among 4 polled investment analysts is to Hold stock in Conatus Pharmaceuticals Inc. This rating has held steady since March, when it was downgraded from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.